EUDA Health Launches Nationwide Stem Cell and Cryostorage Platform in China

EUDA Health Holdings ( (EUDA) ) just unveiled an update.

On December 30, 2025, EUDA Health Holdings launched a nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China, partnering with Shenzhen Inno Immune Co., Wuhan Kaien Hospital, Guangdong Wanhai Cell Biotechnology and Shunfeng Cold Chain Logistics to build an integrated, closed-loop infrastructure for regenerative medicine. Centered on centralized processing and cryostorage hubs in Shenzhen and Wuhan, and supported by a network of some 200 preparation and treatment clinics across more than 20 provinces, the platform is designed to provide long-term stem cell preservation and decentralized clinical access, strengthening EUDA’s position in China’s longevity and regenerative medicine markets and potentially enhancing its competitive footprint in non-invasive, preventive healthcare across the region.

The most recent analyst rating on (EUDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on EUDA Health Holdings stock, see the EUDA Stock Forecast page.

More about EUDA Health Holdings

EUDA Health Holdings Limited is a Singapore-based non-invasive healthcare provider operating across Singapore, Malaysia and China, with a strategic focus on preventive healthcare and the fast-growing longevity sector. Listed on NASDAQ, the company targets the evolving health needs of an aging population of more than 1.8 billion people in the region by offering innovative, science-backed health solutions that shift care from reactive treatment to proactive, longevity-focused programs, and it also runs a Singapore-based property management business.

Average Trading Volume: 258,245

Technical Sentiment Signal: Sell

Current Market Cap: $88.47M

For detailed information about EUDA stock, go to TipRanks’ Stock Analysis page.